Pertuzumab zuvotolimod

N/A

Report date: 2024/02/05 14:09:01

Base Information

Drug NamePertuzumab zuvotolimod

Drug Alias NameSBT-6050SBT6050

ClassificationBiologics > Protein drugs > Immunoglobulin > Antibody > Antibody conjugate > Antibody drug conjugate (ADC) > Linker > Cleavable linkerBiologics > Protein drugs > Immunoglobulin > Antibody > Antibody conjugate > Antibody drug conjugate (ADC)

Mechanisms of ActionToll like receptor 8 agonistsReceptor protein-tyrosine kinase erbB-2 antagonists

TargetsToll like receptor 8Receptor protein-tyrosine kinase erbB-2

Therapy Area/IndicationsSolid tumoursCarcinoma, Non-Small-Cell LungStomach Neoplasms +[5]

Global Approved IndicationsN/A

Approved Indications in ChinaN/A

Original Approved Country/TerritoryN/A

Original Approved DateN/A

Country/TerritoryUnited StatesAustraliaSouth Korea

CombinationsNo

Global Highest StatusDiscontinued (Phase 2 Clinical)

Highest Status in ChinaN/A

Originator CompaniesSilverback Therapeutics Inc

China Registration ClassN/A

Develop Information

Active CompaniesN/A

Inactive CompaniesSilverback Therapeutics Inc

Active IndicationsN/A

Inactive IndicationsSolid tumoursCarcinoma, Non-Small-Cell LungStomach Neoplasms +[5]

Other Information

ATC CodeN/A